Trial Search Results
Contrast-Enhanced Ultrasound Imaging in Diagnosing Liver Cancer in Patients With Cirrhosis
This clinical trial studies how well contrast-enhanced ultrasound imaging works in diagnosing liver cancer in patients with cirrhosis. Diagnostic procedures, such as contrast-enhanced ultrasound imaging, may help find and diagnose liver cancer.
Stanford is currently not accepting patients for this trial.
Sidney Kimmel Cancer Center at Thomas Jefferson University
Collaborator: National Cancer Institute (NCI)
- Procedure: Dynamic Contrast-Enhanced Ultrasound Imaging
- Capable of making informed decisions regarding his/her treatment
- Have known cirrhosis or other risk factors for HCC, based on American Association for
the Study of Liver Diseases (AASLD) and European Association for the Study of the
Liver (EASL) guidelines (applicable in each site jurisdictions)
- Patients with untreated focal liver observations on liver ultrasound or multiphase
contrast-enhanced CT or MRI performed as part of clinical standard of care within 4
weeks before patient enrollment.
• Patients with untreated focal liver observations scheduled for follow-up multiphase
contrast-enhanced CT or MRI, biopsy or surgical excision as part of clinical standard of
care. CEUS should be performed within 4 weeks before or after follow-up imaging or within 4
weeks before biopsy or surgical excision.
- Patients who are pregnant or lactating
- Patients with focal liver observations less than 5 mm or greater than 5 cm in size
- Patients with contraindications to CEUS
- Patients with contraindications to both CT and MRI
- Patients who are medically unstable, terminally ill, or whose clinical course is
- Liver nodule previously treated with trans-arterial or thermal ablation
- Patients who have received an investigational drug in the 30 days before CEUS, or will
receive one within 72 hour after their CEUS exam
Ages Eligible for Study
21 Years - N/A
Genders Eligible for Study